VYNE Therapeutics Inc.(VYNE)

$28.56—

Chart

VYNE Therapeutics Inc.(VYNE)

NASDAQ

$28.56—

Chart Studio

VYNE(VYNE)

VYNE

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Analyst Sentiment

Wall St. Consensus

Buy

2 analysts·Low coverage

Score

1 Buy (50%)1 Hold (50%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

150%

Hold

150%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$5.75

-79.9%

Consensus

$5.75

-79.9%

Bull

$5.75

-79.9%

12-Month Target Range2 analysts

$5.75$5.75$5.75

Current $28.56Consensus

Current Price

$28.56

Above Consensus

$22.81

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+2828.57%

EPS—

FY2028

Rev+32.68%

EPS—

FY2029

Rev+267.65%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$350,000	$10M	$14M	$50M	$396,846
Low	$350,000	$10M	$14M	$50M	$396,846
High	$350,000	$10M	$14M	$50M	$396,846
EBITDA Avg	$-350,000	$-10M	$-14M	$-50M	$-396,846
Low	$-350,000	$-10M	$-14M	$-50M	$-396,846
High	$-350,000	$-10M	$-14M	$-50M	$-396,846
EBIT Avg	$-350,000	$-10M	$-14M	$-50M	$-396,846
Low	$-350,000	$-10M	$-14M	$-50M	$-396,846
High	$-350,000	$-10M	$-14M	$-50M	$-396,846
Net Income Avg	$-65M	$-89M	$-81M	$-86M	$-90M
Low	$-65M	$-89M	$-81M	$-86M	$-90M
High	$-65M	$-89M	$-81M	$-86M	$-90M
EPS Avg	$-76.00	$-104.25	$-95.00	$-100.00	$-105.00
Low	$-76.00	$-104.25	$-95.00	$-100.00	$-105.00
High	$-76.00	$-104.25	$-95.00	$-100.00	$-105.00
Analysts (Rev / EPS)	2 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$200,000	$200,000	$539,867	$530,181	$520,668	$511,327
Low	$200,000	$200,000	$539,867	$530,181	$520,668	$511,327
High	$200,000	$200,000	$539,867	$530,181	$520,668	$511,327
EBITDA Avg	$-200,000	$-200,000	$-539,867	$-530,181	$-520,668	$-511,327
Low	$-200,000	$-200,000	$-539,867	$-530,181	$-520,668	$-511,327
High	$-200,000	$-200,000	$-539,867	$-530,181	$-520,668	$-511,327
EBIT Avg	$-200,000	$-200,000	$-539,867	$-530,181	$-520,668	$-511,327
Low	$-200,000	$-200,000	$-539,867	$-530,181	$-520,668	$-511,327
High	$-200,000	$-200,000	$-539,867	$-530,181	$-520,668	$-511,327
Net Income Avg	$-727,073	$-1M	$-1M	$-1M	$-1M	$-1M
Low	$-727,073	$-1M	$-1M	$-1M	$-1M	$-1M
High	$-727,073	$-1M	$-1M	$-1M	$-1M	$-1M
EPS Avg	$-17.00	$-30.00	$-30.50	$-31.50	$-32.00	$-32.50
Low	$-17.00	$-30.00	$-30.50	$-31.50	$-32.00	$-32.50
High	$-17.00	$-30.00	$-30.50	$-31.50	$-32.00	$-32.50
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Jun 14, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on VYNE Therapeutics (VYNE)

Target:$5.75

+172.5%from $2.11

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance